RxDoctor Payments Data

Susan Campanile, MD

Internal Medicine · Eastchester, NYNPI 1598827628

Payments from drug & device makers

$3,221in general payments, 2019–2025

Across 155 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$598
  • Novartis$515
  • Boehringer Ingelheim$371
  • GSK$203
  • Abbott$195
  • AbbVie$175
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,221 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$185,849
Medicare patients
373
Services billed
2,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$43,164
EliquisApixaban38$40,549
JardianceEmpagliflozin31$32,847
EntrestoSacubitril/Valsartan13$10,723
Rosuvastatin Calcium363$5,187
Levothyroxine Sodium227$5,038
SynthroidLevothyroxine Sodium80$3,538
Atorvastatin Calcium338$2,874
Olmesartan Medoxomil157$2,322
Amlodipine Besylate346$2,068
Escitalopram Oxalate189$1,957
Metoprolol Succinate163$1,935
BystolicNebivolol Hcl11$1,907
Ezetimibe72$1,867
Omeprazole104$1,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$598$43,16444 claims
PfizerEliquis$81$40,54938 claims
Boehringer IngelheimJardiance$371$32,84731 claims
NovartisEntresto$515$10,72313 claims
AbbVieSynthroid$175$3,53880 claims
Kowa Pharmaceuticals America, Inc.Bystolic$51$1,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Eastchester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →